UBS Group
XYN

UBS Group’s Xynomic Pharmaceuticals Holdings, Inc. Common Stock XYN Stock Holding History

UBS Group’s Portfolio XYN Stock Details XYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,357
Closed -$5K – 8583
2019
Q2 		$5K Buy
+1,357
New +$4.41K ﹤0.01% 7425

UBS Group's XYN Position: Q3 2019 in Review

UBS Group sold out of Xynomic Pharmaceuticals Holdings, Inc. Common Stock (XYN) in Q3 2019, closing a stake of 1,357 shares — an estimated $5K sold.

UBS Group first reported a position in XYN in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 0 funds tracked by Wall St. Rank hold XYN as of Q3 2019.

  • UBS Group reported no remaining Xynomic Pharmaceuticals Holdings, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • UBS Group sold 1,357 Xynomic Pharmaceuticals Holdings, Inc. Common Stock shares in Q3 2019, an estimated $5K.
  • UBS Group first reported a position in Xynomic Pharmaceuticals Holdings, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • UBS Group's Xynomic Pharmaceuticals Holdings, Inc. Common Stock position peaked at $5K in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Xynomic Pharmaceuticals Holdings, Inc. Common Stock as of Q3 2019.

Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.